PMID- 12480550
OWN - NLM
STAT- MEDLINE
DCOM- 20030213
LR  - 20190612
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 300
IP  - 1
DP  - 2003 Jan 3
TI  - Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone 
      deacetylase inhibitor, via suppression of HIF-1alpha activity.
PG  - 241-6
AB  - Hypoxia is generally detected in central regions of solid tumors and regulates a 
      variety of transcription factors including hypoxia-inducible factor-1 (HIF-1). 
      HIF-1 plays a pivotal role in cellular response to low oxygen concentration, such 
      as angiogenesis in tumor. Here, we found that a histone deacetylase (HDAC) 
      inhibitor, FK228, inhibits the induction and activity of HIF-1 in response to 
      hypoxia. Moreover, FK228 significantly suppressed the induction of vascular 
      endothelial growth factor (VEGF) under hypoxia, suggesting that FK228 contributes 
      to the inhibition of tumor angiogenesis. In Lewis lung carcinoma model, FK228 
      also blocked angiogenesis induced by hypoxia. These results suggest that FK228 
      can downregulate hypoxia-responsive angiogenesis through suppression of 
      HIF-1alpha activity.
FAU - Mie Lee, You
AU  - Mie Lee Y
AD  - Angiogenesis Research Laboratory, Research Institute of Phamaceutical Sciences 
      and College of Pharmacy, Seoul National University, South Korea.
FAU - Kim, Se-Hee
AU  - Kim SH
FAU - Kim, Hae-Sun
AU  - Kim HS
FAU - Jin Son, Myung
AU  - Jin Son M
FAU - Nakajima, Hidenori
AU  - Nakajima H
FAU - Jeong Kwon, Ho
AU  - Jeong Kwon H
FAU - Kim, Kyu-Won
AU  - Kim KW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Depsipeptides)
RN  - 0 (Endothelial Growth Factors)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Lymphokines)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Vascular Endothelial Growth Factors)
RN  - CX3T89XQBK (romidepsin)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/*pharmacology
MH  - *Depsipeptides
MH  - Endothelial Growth Factors/genetics/metabolism
MH  - Enzyme Inhibitors/pharmacology
MH  - Gene Expression/drug effects
MH  - *Histone Deacetylase Inhibitors
MH  - Hypoxia/*complications/genetics/metabolism
MH  - Hypoxia-Inducible Factor 1, alpha Subunit
MH  - Intercellular Signaling Peptides and Proteins/genetics/metabolism
MH  - Lung Neoplasms/blood supply/pathology
MH  - Lymphokines/genetics/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neovascularization, Pathologic/etiology/pathology/*prevention & control
MH  - *Peptides, Cyclic
MH  - RNA, Messenger/genetics/metabolism
MH  - Transcription Factors/*antagonists & inhibitors
MH  - Tumor Cells, Cultured
MH  - Vascular Endothelial Growth Factor A
MH  - Vascular Endothelial Growth Factors
EDAT- 2002/12/14 04:00
MHDA- 2003/02/14 04:00
CRDT- 2002/12/14 04:00
PHST- 2002/12/14 04:00 [pubmed]
PHST- 2003/02/14 04:00 [medline]
PHST- 2002/12/14 04:00 [entrez]
AID - S0006291X02027870 [pii]
AID - 10.1016/s0006-291x(02)02787-0 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2003 Jan 3;300(1):241-6. doi: 
      10.1016/s0006-291x(02)02787-0.